drugset / Trial / NCT01190007
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 2.5 mg | — |
| Subject | Amlodipine | Other / unclassified | 5 mg | — |
| Subject | Atorvastatin | Small molecule | 5 mg | — |
| Subject | Atorvastatin | Small molecule | 10 mg | — |